NeonMind Biosciences Inc. (CSE: NEON, OTC: NMDBF) is engaged in the research and development of products to optimize human health and performance. The company believes a substance called psilocybin can play a role in treating the mental health issues around obesity. Obesity is an epidemic that is responsible for 37% of the global burden of disease. Being overweight puts people at risk for the development of a number of chronic diseases; cardiovascular disease, diabetes, osteoarthritis, and some types of cancer. It’s also not an easy issue for people to fix on their own. Furthermore, traditional weight loss methods don’t work for everyone, and often don’t address the mental health issues that are sometimes tied to obesity. “We envision operating a leading chain of NeonMind branded mental health clinics across Canada that is successfully delivering care that otherwise would not have been available to patients with mental health conditions,” says President and CEO, Rob Tessarolo. For more information: https://b-tv.com/neonmind-biosciences-psychedelics-btv-ep-359/ Subscribe to receive more investment opportunities videos: http://bit.ly/Subscribe2BTV Check out more videos: BTV Business Television episodes: http://bit.ly/2UBerea CEO Clips: http://bit.ly/2UTdumA New Listing Alert: http://bit.ly/2W1o0ob #NEON #MentalHealth #Stockmarket